8-K Announcements
6Material company update
Apr 21, 2026·SEC
Material company update
Mar 12, 2026·SEC
Material company update
Feb 10, 2026·SEC
Quest Diagnostics Incorporated(DGX)Earnings, Financials & Key Ratios
DGX•NYSE
22.3× P/E·Price updated Jun 19, 2026
AboutQuest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.Show more
- Revenue$11.04B+11.8%
- EBITDA$2.17B+18.2%
- Net Income$992M+13.9%
- EPS (Diluted)8.75+13.8%
- Gross Margin31.93%-2.8%
- EBITDA Margin19.69%+5.7%
- Operating Margin14.53%+6.5%
- Net Margin8.99%+1.9%
- ROE13.99%+6.9%
DGX Key Insights
Quest Diagnostics Incorporated (DGX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓14 consecutive years of dividend growth
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy 5Y average net margin of 11.0%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DGX Price & Volume
Quest Diagnostics Incorporated (DGX) stock price & volume — 10-year historical chart
Loading chart...
DGX Growth Metrics
Quest Diagnostics Incorporated (DGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.95%
5 Years3.18%
3 Years3.74%
TTM11.03%
Profit CAGR
10 Years3.42%
5 Years-7.07%
3 Years1.6%
TTM14.16%
EPS CAGR
10 Years6.03%
5 Years-3.62%
3 Years3.12%
TTM14.27%
Return on Capital
10 Years13.22%
5 Years12.92%
3 Years10.83%
Last Year11.48%
DGX Recent Earnings
Quest Diagnostics Incorporated (DGX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 12/12 qtrs (100%)
Q2 2026Latest
Apr 21, 2026Metric
Actual
Est
EPS
$2.50+5.5%
$2.37
Rev
$2.9B+2.3%
$2.8B
Q1 2026
Feb 10, 2026Metric
Actual
Est
EPS
$2.42+2.5%
$2.36
Rev
$2.8B+1.9%
$2.8B
Q4 2025
Oct 21, 2025Metric
Actual
Est
EPS
$2.60+4.0%
$2.50
Rev
$2.8B+2.9%
$2.7B
Q3 2025
Jul 22, 2025Metric
Actual
Est
EPS
$2.62+1.9%
$2.57
Rev
$2.8B+1.3%
$2.7B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 21, 2026 | $2.50vs $2.37+5.5% | $2.9Bvs $2.8B+2.3% |
| Q1 2026 | Feb 10, 2026 | $2.42vs $2.36+2.5% | $2.8Bvs $2.8B+1.9% |
| Q4 2025 | Oct 21, 2025 | $2.60vs $2.50+4.0% | $2.8Bvs $2.7B+2.9% |
| Q3 2025 | Jul 22, 2025 | $2.62vs $2.57+1.9% | $2.8Bvs $2.7B+1.3% |
Based on last 12 quarters of dataView full earnings history →
DGX Peer Comparison
Quest Diagnostics Incorporated (DGX) competitors in Clinical and Specialty Lab Testing — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 LH | 21.05B | 255.82 | 24.46 | 7.25% | 6.66% | 10.89% | 0.83 | |
 SLNO | 2.76B | 53.01 | 135.92 | 33.7% | 22.86% | 0.01 | ||
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 BIO | 7.63B | 282.44 | 10.13 | 0.65% | 6.52% | 2.4% | 0.21 | |
 NEOG | 2.03B | 9.31 | -1.85 | -3.2% | -68.47% | -28.64% | 0.44 | |
 QDEL | 930.68M | 13.67 | -0.82 | -1.89% | -45.57% | -56.31% | 1.46 | |
 MYRG | 7.18B | 461.10 | 61.24 | 8.79% | 3.71% | 22.14% | 0.16 | |
 CERS | 541M | 2.70 | -32.93 | 14.35% | -4.41% | -15.18% | 1.49 |
Compare DGX vs Peers
Quest Diagnostics Incorporated (DGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DGX Income Statement
Quest Diagnostics Incorporated (DGX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 7.71B | 7.53B | 7.73B | 9.44B | 10.79B | 9.88B | 9.25B | 9.87B | 11.04B | 11.28B |
Revenue Growth % | 2.58% | -2.31% | 2.59% | 22.15% | 14.32% | -8.39% | -6.38% | 6.7% | 11.78% | 11.03% |
Cost of Goods Sold | 4.72B | 4.93B | 5.04B | 5.8B | 6.58B | 6.45B | 6.2B | 6.63B | 7.51B | 7.53B |
COGS % of Revenue | 61.21% | 65.41% | 65.2% | 61.5% | 60.98% | 65.26% | 67% | 67.14% | 68.07% | - |
Gross Profit | 2.99B▲ 0% | 2.6B▼ 12.9% | 2.69B▲ 3.2% | 3.63B▲ 35.1% | 4.21B▲ 15.9% | 3.43B▼ 18.4% | 3.07B▼ 10.6% | 3.24B▲ 5.7% | 3.52B▲ 8.6% | 3.75B▲ 0% |
Gross Margin % | 38.79% | 34.59% | 34.8% | 38.5% | 39.02% | 34.74% | 33.17% | 32.86% | 31.93% | 33.23% |
Gross Profit Growth % | 3.14% | -12.88% | 3.22% | 35.11% | 15.85% | -18.44% | -10.6% | 5.7% | 8.6% | - |
Operating Expenses | 1.82B | 1.5B | 1.46B | 1.66B | 1.83B | 2B | 1.81B | 1.9B | 1.92B | 2.13B |
OpEx % of Revenue | 23.67% | 19.92% | 18.87% | 17.61% | 16.94% | 20.29% | 19.53% | 19.23% | 17.4% | - |
Selling, General & Admin | 1.75B | 1.42B | 1.46B | 1.55B | 1.73B | 1.87B | 1.61B | 1.77B | 1.97B | 1.98B |
SG&A % of Revenue | 22.7% | 18.91% | 18.86% | 16.42% | 16.01% | 18.96% | 17.46% | 17.93% | 17.83% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 16M | -8M | 1M | 112M | 101M | 131M | 192M | 128M | -47M | 4M |
Operating Income | 1.17B▲ 0% | 1.1B▼ 5.5% | 1.23B▲ 11.8% | 1.97B▲ 60.1% | 2.38B▲ 20.8% | 1.43B▼ 40.0% | 1.26B▼ 11.6% | 1.35B▲ 6.7% | 1.6B▲ 19.1% | 1.61B▲ 0% |
Operating Margin % | 15.11% | 14.62% | 15.93% | 20.89% | 22.07% | 14.45% | 13.64% | 13.63% | 14.53% | 14.31% |
Operating Income Growth % | -8.77% | -5.49% | 11.81% | 60.11% | 20.8% | -40.03% | -11.62% | 6.66% | 19.09% | - |
EBITDA | 1.44B | 1.41B | 1.56B | 2.33B | 2.79B | 1.86B | 1.7B | 1.84B | 2.17B | 1.95B |
EBITDA Margin % | 18.61% | 18.72% | 20.19% | 24.71% | 25.85% | 18.87% | 18.39% | 18.63% | 19.69% | 17.25% |
EBITDA Growth % | -5.96% | -1.74% | 10.64% | 49.49% | 19.6% | -33.13% | -8.79% | 8.11% | 18.16% | 1.94% |
D&A (Non-Cash Add-back) | 270M | 309M | 329M | 361M | 408M | 437M | 439M | 493M | 570M | 322M |
EBIT | 1.18B | 1.09B | 1.26B | 2.05B | 2.75B | 1.38B | 1.29B | 1.4B | 1.62B | 1.66B |
Net Interest Income | -151M | -167M | -175M | -163M | -151M | -138M | -152M | -201M | -264M | -260M |
Interest Income | 2M | 2M | 5M | 3M | 1M | 10M | 11M | 25M | 0 | 5M |
Interest Expense | 153M | 169M | 180M | 166M | 152M | 148M | 163M | 226M | 264M | 265M |
Other Income/Expense | -135M | -175M | -98M | -12M | 296M | -149M | -106M | -152M | -243M | -214M |
Pretax Income | 1.03B▲ 0% | 926M▼ 10.1% | 1.13B▲ 22.4% | 1.96B▲ 72.9% | 2.68B▲ 36.7% | 1.28B▼ 52.2% | 1.16B▼ 9.6% | 1.19B▲ 3.3% | 1.36B▲ 13.9% | 1.4B▲ 0% |
Pretax Margin % | 13.36% | 12.3% | 14.66% | 20.76% | 24.81% | 12.94% | 12.49% | 12.09% | 12.32% | 12.41% |
Income Tax | 241M | 182M | 247M | 460M | 597M | 264M | 248M | 273M | 314M | 329M |
Effective Tax Rate % | 23.4% | 19.65% | 21.8% | 23.48% | 22.3% | 20.64% | 21.45% | 22.86% | 23.09% | 23.5% |
Net Income | 772M▲ 0% | 736M▼ 4.7% | 858M▲ 16.6% | 1.43B▲ 66.8% | 2B▲ 39.4% | 946M▼ 52.6% | 854M▼ 9.7% | 871M▲ 2.0% | 992M▲ 13.9% | 1.02B▲ 0% |
Net Margin % | 10.01% | 9.77% | 11.11% | 15.16% | 18.49% | 9.57% | 9.23% | 8.82% | 8.99% | 9.08% |
Net Income Growth % | 19.69% | -4.66% | 16.58% | 66.78% | 39.41% | -52.58% | -9.73% | 1.99% | 13.89% | 14.16% |
Net Income (Continuing) | 824M | 788M | 886M | 1.5B | 2.08B | 1.01B | 908M | 921M | 1.05B | 1.07B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 114M | 128M | 122M | 132M | 118M | 114M | 111M | 118M | 116M | 300M |
EPS (Diluted) | 5.50▲ 0% | 5.29▼ 3.8% | 6.29▲ 18.9% | 10.52▲ 67.2% | 15.53▲ 47.6% | 7.98▼ 48.6% | 7.52▼ 5.8% | 7.69▲ 2.3% | 8.75▲ 13.8% | 9.14▲ 0% |
EPS Growth % | 21.95% | -3.82% | 18.9% | 67.25% | 47.62% | -48.62% | -5.76% | 2.26% | 13.78% | 14.27% |
EPS (Basic) | 5.63 | 5.41 | 6.38 | 10.68 | 15.90 | 8.12 | 7.59 | 7.80 | 8.87 | - |
Diluted Shares Outstanding | 140M | 139M | 136M | 136M | 128M | 118M | 113M | 113M | 113M | 112M |
Basic Shares Outstanding | 137M | 136M | 134M | 134M | 125M | 116M | 112M | 111M | 111M | 110M |
Dividend Payout Ratio | 31.99% | 36.14% | 33.33% | 20.75% | 15.49% | 32.24% | 36.77% | 38% | 35.58% | - |
DGX Balance Sheet
Quest Diagnostics Incorporated (DGX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.31B | 1.39B | 2.49B | 3.06B | 2.74B | 1.9B | 2.37B | 2.39B | 2.38B | 2.57B |
Cash & Short-Term Investments | 137M | 135M | 1.19B | 1.16B | 872M | 315M | 686M | 549M | 420M | 393M |
Cash Only | 137M | 135M | 1.19B | 1.16B | 872M | 315M | 686M | 549M | 420M | 393M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 924M | 1.01B | 1.06B | 1.52B | 1.44B | 1.2B | 1.21B | 1.3B | 1.41B | 1.59B |
Days Sales Outstanding | 43.75 | 49.05 | 50.22 | 58.79 | 48.65 | 44.13 | 47.74 | 48.21 | 46.57 | 47.49 |
Inventory | 95M | 99M | 123M | 223M | 208M | 192M | 190M | 188M | 189M | 225M |
Days Inventory Outstanding | 7.35 | 7.34 | 8.91 | 14.02 | 11.54 | 10.87 | 11.19 | 10.35 | 9.18 | 9.54 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 196M | 286M | 351M | 361M | 361M |
Total Non-Current Assets | 9.2B | 9.61B | 10.35B | 10.97B | 10.87B | 10.94B | 11.65B | 13.76B | 13.85B | 14.11B |
Property, Plant & Equipment | 1.15B | 1.29B | 1.97B | 2.23B | 2.3B | 2.35B | 2.42B | 2.76B | 2.86B | 2.88B |
Fixed Asset Turnover | 6.73x | 5.85x | 3.92x | 4.23x | 4.68x | 4.20x | 3.83x | 3.57x | 3.86x | 3.99x |
Goodwill | 6.33B | 6.56B | 6.62B | 6.87B | 7.09B | 7.22B | 7.73B | 8.86B | 8.95B | 9.12B |
Intangible Assets | 1.12B | 1.21B | 1.12B | 1.17B | 1.17B | 1.09B | 1.17B | 1.76B | 1.64B | 1.72B |
Long-Term Investments | 462M | 436M | 482M | 521M | 141M | 132M | 135M | 123M | 136M | 543M |
Other Non-Current Assets | 132M | 119M | 160M | 176M | 163M | 144M | 198M | 255M | 270M | 256M |
Total Assets | 10.5B▲ 0% | 11B▲ 4.8% | 12.84B▲ 16.7% | 14.03B▲ 9.2% | 13.61B▼ 3.0% | 12.84B▼ 5.7% | 14.02B▲ 9.2% | 16.15B▲ 15.2% | 16.23B▲ 0.4% | 16.67B▲ 0% |
Asset Turnover | 0.73x | 0.68x | 0.60x | 0.67x | 0.79x | 0.77x | 0.66x | 0.61x | 0.68x | 0.69x |
Asset Growth % | 3.99% | 4.76% | 16.72% | 9.21% | -2.96% | -5.69% | 9.23% | 15.2% | 0.45% | 21.67% |
Total Current Liabilities | 1.06B | 1.49B | 1.99B | 1.78B | 1.75B | 1.55B | 1.81B | 2.17B | 2.28B | 2.18B |
Accounts Payable | 224M | 222M | 263M | 446M | 357M | 324M | 378M | 287M | 1.6B | 1.5B |
Days Payables Outstanding | 17.33 | 16.45 | 19.06 | 28.05 | 19.81 | 18.33 | 22.26 | 15.8 | 77.74 | 71.09 |
Short-Term Debt | 107M | 562M | 1.04B | 296M | 269M | 247M | 585M | 937M | 678M | 677M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 392M | 435M | 376M | 489M | 599M | 550M | 471M | 466M | 0 | 0 |
Current Ratio | 1.24x | 0.94x | 1.25x | 1.72x | 1.56x | 1.22x | 1.31x | 1.10x | 1.04x | 1.18x |
Quick Ratio | 1.15x | 0.87x | 1.19x | 1.60x | 1.44x | 1.10x | 1.20x | 1.02x | 0.96x | 1.08x |
Cash Conversion Cycle | 33.77 | 39.93 | 40.07 | 44.77 | 40.39 | 36.66 | 36.67 | 42.76 | -21.99 | -14.05 |
Total Non-Current Liabilities | 4.41B | 4.17B | 5.09B | 5.36B | 5.3B | 5.28B | 5.79B | 7.09B | 6.66B | 6.83B |
Long-Term Debt | 3.75B | 3.4B | 3.94B | 3.99B | 4.01B | 3.98B | 4.41B | 5.6B | 5.7B | 5.73B |
Capital Lease Obligations | 0 | 32M | 443M | 524M | 494M | 489M | 503M | 551M | 537M | 2.19B |
Deferred Tax Liabilities | 170M | 243M | 264M | 350M | 290M | 295M | 270M | 250M | 0 | 0 |
Other Non-Current Liabilities | 493M | 502M | 447M | 497M | 502M | 517M | 606M | 688M | 420M | 527M |
Total Liabilities | 5.47B | 5.66B | 7.08B | 7.13B | 7.05B | 6.83B | 7.6B | 9.26B | 8.94B | 9.01B |
Total Debt | 3.85B | 3.99B | 5.42B | 4.81B | 4.77B | 4.71B | 5.5B | 7.09B | 6.92B | 6.98B |
Net Debt | 3.72B | 3.86B | 4.22B | 3.65B | 3.9B | 4.4B | 4.81B | 6.54B | 6.5B | 6.59B |
Debt / Equity | 0.77x | 0.75x | 0.94x | 0.70x | 0.73x | 0.78x | 0.86x | 1.03x | 0.95x | 0.91x |
Debt / EBITDA | 2.69x | 2.83x | 3.47x | 2.06x | 1.71x | 2.53x | 3.23x | 3.85x | 3.18x | 3.59x |
Net Debt / EBITDA | 2.59x | 2.73x | 2.71x | 1.57x | 1.40x | 2.36x | 2.83x | 3.56x | 2.99x | 3.38x |
Interest Coverage | 7.73x | 6.48x | 6.98x | 12.35x | 18.10x | 9.34x | 7.93x | 6.20x | 6.15x | 6.26x |
Total Equity | 5.04B▲ 0% | 5.34B▲ 6.1% | 5.76B▲ 7.8% | 6.89B▲ 19.6% | 6.56B▼ 4.8% | 6.01B▼ 8.5% | 6.42B▲ 6.8% | 6.9B▲ 7.4% | 7.29B▲ 5.7% | 7.67B▲ 0% |
Equity Growth % | 6.29% | 6.14% | 7.84% | 19.57% | -4.77% | -8.46% | 6.84% | 7.45% | 5.66% | 30.15% |
Book Value per Share | 35.96 | 38.45 | 42.38 | 50.67 | 51.27 | 50.91 | 56.80 | 61.03 | 64.48 | 68.45 |
Total Shareholders' Equity | 4.92B | 5.22B | 5.64B | 6.76B | 6.44B | 5.89B | 6.31B | 6.78B | 7.17B | 7.37B |
Common Stock | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M | 2M |
Retained Earnings | 7.14B | 7.6B | 8.17B | 9.3B | 7.65B | 8.29B | 8.82B | 9.36B | 9.99B | 10.15B |
Treasury Stock | -4.78B | -5B | -5.22B | -5.37B | -3.45B | -4.67B | -4.83B | -4.86B | -5.18B | -5.09B |
Accumulated OCI | -48M | -59M | -39M | -21M | -14M | -21M | -14M | -88M | -27M | -43M |
Minority Interest | 114M | 128M | 122M | 132M | 118M | 114M | 111M | 118M | 116M | 300M |
DGX Cash Flow Statement
Quest Diagnostics Incorporated (DGX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.18B | 1.2B | 1.24B | 2B | 2.23B | 1.72B | 1.27B | 1.33B | 1.89B | 1.85B |
Operating CF Margin % | 15.24% | 15.93% | 16.09% | 21.25% | 20.7% | 17.38% | 13.75% | 13.51% | 17.09% | - |
Operating CF Growth % | 9.92% | 2.13% | 3.58% | 61.3% | 11.37% | -23.06% | -25.96% | 4.87% | 41.38% | 98.01% |
Net Income | 824M | 788M | 906M | 1.5B | 2.08B | 1.01B | 908M | 921M | 1.05B | 1.02B |
Depreciation & Amortization | 270M | 309M | 329M | 361M | 408M | 437M | 439M | 493M | 570M | 432M |
Stock-Based Compensation | 79M | 61M | 56M | 97M | 79M | 77M | 77M | 88M | 88M | 61M |
Deferred Taxes | 9M | 73M | 15M | 85M | -57M | 1M | -49M | 13M | 105M | 146M |
Other Non-Cash Items | 309M | 18M | -98M | -59M | -364M | 69M | 42M | 20M | 27M | 203M |
Working Capital Changes | -316M | -49M | 35M | 22M | 87M | 119M | -145M | -201M | 50M | -56M |
Change in Receivables | -298M | -65M | -63M | -455M | 81M | 246M | -15M | -71M | -106M | -185M |
Change in Inventory | 16M | 4M | 29M | 0 | -20M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -8M | -19M | 73M | 452M | 35M | -149M | -55M | -67M | 129M | 170M |
Cash from Investing | -805M | -801M | -411M | -772M | 21M | -543M | -1.06B | -2.55B | -631M | -668M |
Capital Expenditures | -252M | -383M | -400M | -418M | -403M | -404M | -408M | -425M | -527M | -524M |
CapEx % of Revenue | 3.27% | 5.09% | 5.18% | 4.43% | 3.74% | 4.09% | 4.41% | 4.31% | 4.78% | 4.65% |
Acquisitions | -555M | -419M | -58M | -330M | 424M | -144M | -611M | -2.16B | -101M | -139M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -252M | -383M | -309M | -415M | -400M | 5M | -42M | 41M | -3M | -5M |
Cash from Financing | -592M | -401M | 225M | -1.27B | -2.54B | -1.73B | 160M | 1.08B | -1.39B | -979M |
Debt Issued (Net) | 23M | 124M | 832M | -805M | -2M | -2M | 748M | 1.54B | -602M | -218M |
Equity Issued (Net) | -465M | -322M | -353M | -325M | -2.2B | -1.41B | -275M | -151M | -371M | -354M |
Dividends Paid | -247M | -266M | -286M | -297M | -309M | -305M | -314M | -331M | -353M | -357M |
Share Repurchases | -465M | -322M | -353M | -325M | -2.2B | -1.41B | -275M | -151M | -450M | -450M |
Other Financing | 97M | 63M | 32M | 160M | -30M | -17M | 1M | 23M | -62M | -50M |
Net Change in Cash | -222M▲ 0% | -2M▲ 99.1% | 1.06B▲ 52950.0% | -34M▼ 103.2% | -286M▼ 741.2% | -557M▼ 94.8% | 371M▲ 166.6% | -137M▼ 136.9% | -129M▲ 5.8% | 205M▲ 0% |
Free Cash Flow | 923M▲ 0% | 817M▼ 11.5% | 843M▲ 3.2% | 1.59B▲ 88.3% | 1.83B▲ 15.3% | 1.31B▼ 28.2% | 864M▼ 34.2% | 909M▲ 5.2% | 1.36B▲ 49.5% | 1.33B▲ 0% |
FCF Margin % | 11.97% | 10.85% | 10.91% | 16.82% | 16.96% | 13.3% | 9.34% | 9.21% | 12.32% | 11.76% |
FCF Growth % | 18.94% | -11.48% | 3.18% | 88.26% | 15.31% | -28.2% | -34.25% | 5.21% | 49.5% | 25.57% |
FCF per Share | 6.59 | 5.88 | 6.20 | 11.67 | 14.30 | 11.14 | 7.65 | 8.04 | 12.03 | 11.84 |
FCF Conversion (FCF/Net Income) | 1.52x | 1.63x | 1.45x | 1.40x | 1.12x | 1.82x | 1.49x | 1.53x | 1.90x | 1.29x |
Interest Paid | 159M | 0 | 0 | 0 | 159M | 156M | 134M | 262M | 0 | 157M |
Taxes Paid | 243M | 0 | 0 | 0 | 283M | 283M | 317M | 256M | 0 | 116M |
DGX Key Ratios
Quest Diagnostics Incorporated (DGX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 15.8% | 14.18% | 15.45% | 22.62% | 29.66% | 15.05% | 13.75% | 13.08% | 13.99% | 13.8% |
Return on Invested Capital (ROIC) | 10.36% | 9.2% | 9.62% | 14.4% | 17% | 10.26% | 8.75% | 8.19% | 8.83% | 8.84% |
Gross Margin | 38.79% | 34.59% | 34.8% | 38.5% | 39.02% | 34.74% | 33.17% | 32.86% | 31.93% | 33.23% |
Net Margin | 10.01% | 9.77% | 11.11% | 15.16% | 18.49% | 9.57% | 9.23% | 8.82% | 8.99% | 9.08% |
Debt / Equity | 0.77x | 0.75x | 0.94x | 0.70x | 0.73x | 0.78x | 0.86x | 1.03x | 0.95x | 0.91x |
Interest Coverage | 7.73x | 6.48x | 6.98x | 12.35x | 18.10x | 9.34x | 7.93x | 6.20x | 6.15x | 6.26x |
FCF Conversion | 1.52x | 1.63x | 1.45x | 1.40x | 1.12x | 1.82x | 1.49x | 1.53x | 1.90x | 1.29x |
Revenue Growth | 2.58% | -2.31% | 2.59% | 22.15% | 14.32% | -8.39% | -6.38% | 6.7% | 11.78% | 11.03% |
Related:DGX Dividend History·DGX Revenue History·DGX Price History·DGX P/E History·DGX Financial Ratios·DGX Institutional Holders
DGX SEC Filings & Documents
Quest Diagnostics Incorporated (DGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
DGX Frequently Asked Questions
Quest Diagnostics Incorporated (DGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Quest Diagnostics Incorporated (DGX) reported $11.28B in revenue for fiscal year 2025. This represents a 598% increase from $1.62B in 1996.
Quest Diagnostics Incorporated (DGX) grew revenue by 11.8% over the past year. This is steady growth.
Yes, Quest Diagnostics Incorporated (DGX) is profitable, generating $1.02B in net income for fiscal year 2025 (9.0% net margin).
Dividend & Returns
Yes, Quest Diagnostics Incorporated (DGX) pays a dividend with a yield of 1.60%. This makes it attractive for income-focused investors.
Quest Diagnostics Incorporated (DGX) has a return on equity (ROE) of 14.0%. This is reasonable for most industries.
Quest Diagnostics Incorporated (DGX) generated $1.33B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.